Literature DB >> 9484239

Alzheimer's amyloid precursor protein alpha-secretase is inhibited by hydroxamic acid-based zinc metalloprotease inhibitors: similarities to the angiotensin converting enzyme secretase.

S Parvathy1, I Hussain, E H Karran, A J Turner, N M Hooper.   

Abstract

The 4 kDa beta-amyloid peptide that forms the amyloid fibrils in the brain parenchyma of Alzheimer's disease patients is derived from the larger integral membrane protein, the amyloid precursor protein. In the nonamyloidogenic pathway, alpha-secretase cleaves the amyloid precursor protein within the beta-amyloid domain, releasing an extracellular portion and thereby preventing deposition of the intact amyloidogenic peptide. The release of the amyloid precursor protein from both SH-SY5Y and IMR-32 neuronal cells by alpha-secretase was blocked by batimastat and other related synthetic hydroxamic acid-based zinc metalloprotease inhibitors, but not by the structurally unrelated zinc metalloprotease inhibitors enalaprilat and phosphoramidon. Batimastat inhibited the release of the amyloid precursor protein from both cell lines with an I50 value of 3 microM. Removal of the thienothiomethyl substituent adjacent to the hydroxamic acid moiety or the substitution of the P2' substituent decreased the inhibitory potency of batimastat toward alpha-secretase. In the SH-SY5Y cells, both the basal and the carbachol-stimulated release of the amyloid precursor protein were blocked by batimastat. In contrast, neither the level of full-length amyloid precursor protein nor its cleavage by beta-secretase were inhibited by any of the zinc metalloprotease inhibitors examined. In transfected IMR-32 cells, the release of both the amyloid precursor protein and angiotensin converting enzyme was inhibited by batimastat, marimastat, and BB2116 with I50 values in the low micromolar range, while batimastat and BB2116 inhibited the release of both proteins from HUVECs. The profile of inhibition of alpha-secretase by batimastat and structurally related compounds is identical with that observed with the angiotensin converting enzyme secretase suggesting that the two are closely related zinc metalloproteases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484239     DOI: 10.1021/bi972034y

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  20 in total

1.  Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis.

Authors:  S L Leib; D Leppert; J Clements; M G Täuber
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease.

Authors:  S Lammich; E Kojro; R Postina; S Gilbert; R Pfeiffer; M Jasionowski; C Haass; F Fahrenholz
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

3.  Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-alpha converting enzyme.

Authors:  B E Slack; L K Ma; C C Seah
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

4.  Treatment with BB-94, a broad spectrum inhibitor of zinc-dependent metalloproteinases, causes deviation of the cytokine profile towards type-2 in experimental pulmonary tuberculosis in Balb/c mice.

Authors:  R Hernandez-Pando; H Orozco; K Arriaga; L Pavön; G Rook
Journal:  Int J Exp Pathol       Date:  2000-06       Impact factor: 1.925

5.  Roles of the juxtamembrane and extracellular domains of angiotensin-converting enzyme in ectodomain shedding.

Authors:  S Pang; A J Chubb; S L Schwager; M R Ehlers; E D Sturrock; N M Hooper
Journal:  Biochem J       Date:  2001-08-15       Impact factor: 3.857

6.  Metalloproteases and guidance of retinal axons in the developing visual system.

Authors:  Christine A Webber; Jennifer C Hocking; Voon W Yong; Carrie L Stange; Sarah McFarlane
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

7.  Zinc metalloproteinases and amyloid Beta-Peptide metabolism: the positive side of proteolysis in Alzheimer's disease.

Authors:  Mallory Gough; Catherine Parr-Sturgess; Edward Parkin
Journal:  Biochem Res Int       Date:  2010-09-30

Review 8.  BACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis.

Authors:  Neville Marks; Martin J Berg
Journal:  Neurochem Res       Date:  2009-09-17       Impact factor: 3.996

9.  The role of beta-amyloid protein in synaptic function: implications for Alzheimer's disease therapy.

Authors:  F Peña; Ai Gutiérrez-Lerma; R Quiroz-Baez; C Arias
Journal:  Curr Neuropharmacol       Date:  2006-04       Impact factor: 7.363

10.  Interleukin-1beta enhances nucleotide-induced and alpha-secretase-dependent amyloid precursor protein processing in rat primary cortical neurons via up-regulation of the P2Y(2) receptor.

Authors:  Qiongman Kong; Troy S Peterson; Olga Baker; Emily Stanley; Jean Camden; Cheikh I Seye; Laurie Erb; Agnes Simonyi; W Gibson Wood; Grace Y Sun; Gary A Weisman
Journal:  J Neurochem       Date:  2009-03-20       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.